Examining HIV Diagnosis and Linkage to PrEP Prescription Among Members at An Integrated Health System in the Southeast United States
- PMID: 36097086
- DOI: 10.1007/s10461-022-03812-4
Examining HIV Diagnosis and Linkage to PrEP Prescription Among Members at An Integrated Health System in the Southeast United States
Abstract
Pre-Exposure Prophylaxis (PrEP) is a priority method for preventing HIV infection. This study's aims were threefold: (1) identify characteristics of members of a large health maintenance organization, Kaiser Permanente Georgia (KPGA), associated with HIV infection, (2) identify which member characteristics associated with HIV were also associated with PrEP prescription, and (3) identify which HIV-associated characteristics were associated with under- or over-prescribing of PrEP. Analysis of variables from the electronic medical record revealed that age, race, gender, mental health diagnosis, STI diagnosis, and sexual orientation were independently associated with HIV diagnosis. The same characteristics were independently associated with PrEP prescription except for race. Persons identifying as Black or unknown race, women, and/or heterosexual; and who had an STI diagnosis and/or illicit drug use had lower odds of being prescribed PrEP than of having an HIV diagnosis. The implications of these findings for improving physician identification of candidates for PrEP prescription are discussed.
Keywords: HIV; Pre-Exposure Prophylaxis (PrEP); Prescription; Prevention; Providers.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
References
-
- CDC. Pre-Exposure P, Atlanta. GA: U.S. Department of Health & Human Services; 2018 [Available at: https://www.cdc.gov/hiv/risk/prep/index.html .] Accessed August 4, 2022.
-
- Tanner MR, Miele P, Carter W, et al. Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents: Clinical Considerations, 2020. MMWR Recomm Rep 2020;69(No. RR-3):1–12. DOI: https://doi.org/10.15585/mmwr.rr6903a1 .
-
- FDA approves second drug to. prevent HIV infection as part of ongoing efforts to end the HIV epidemic [press release]. Food and Drug Administration, 2019.[Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-second-... .] Access August 4, 2022.
-
- CDC. PrEP Effectiveness. [Available at: https://www.cdc.gov/hiv/basics/prep/prep-effectiveness.html .] Accessed on August 4, 2022.
-
- Surveillance CDCHIV, Report. 2018 (Updated). MMWR. 2020;Vol.31. [Available at: https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveil... .] Accessed on August 4, 2022.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
